ArticleScientific reports2026
Synthesis, antioxidant and antimicrobial activities, molecular docking study of new pyrimidine derivatives.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Organic compounds, especially heterocyclic compounds, are known for their significant bioactivity, in this work, novel pyrimidine derivatives 3-11 were synthesized from the reaction of chalcon compound 1 with hydrogen peroxide to give oxiran compound 2 which reacted with thiourea producing the precursor key compound 3. Elemental analysis and several spectroscopic techniques were used to determine the molecular structures of the novel derivatives. All the new analogs were screened against four human pathogenic microbial strains: Escherichia coli as Gram-negative bacteria, Bacillus subtilis as Gram-positive bacteria and the yeast Candida albicans and Aspergillus niger using agar diffusion method, suggesting broad-spectrum potential. whereas compounds 5, 9a and 11 exhibited high inhibitory action with an inhibition zone of 17-20 mm compared to standard drugs, Streptomycin and Cycloheximide. Antioxidant profile employing DPPH radical scavenging studies further proved their capacity to lower oxidative stress. Whereas compounds 5, 9a and 11 showed significant DPPH activity and antioxidant activities. Additionally, at doses of 2.0, 1.0, and 0.5 mg/ml, compounds 3, 4, 6a, 8 and 9b showed moderate antioxidant activity. Conversely, compounds 6b, 6c, 7 and 10 showed very little DPPH activity. Molecular docking tests revealed strong binding affinities with significant microbial enzymes, which corroborated these conclusions and were in line with their observed inhibitory effects. Complementary and drug-like in silico ADMET testing confirmed that Lipinski's recommendations were followed, showing that oral delivery was suitable. Some of the produced compounds showed good pharmacological activity when compared to reference controls. A comprehensive synthesis, spectroscopic analyses, and pharmacological activity were all reported.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.